We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Transcription Factor Genes Kill Tumors

By Biotechdaily staff writers
Posted on 15 Feb 2005
Cancer researchers working with a rodent model for prostate cancer have used an adenovirus vector to implant the genes for two transcription factors, PEA-3 and AP-1, which selectively activated a tumor-suppressing gene and eradicated the cancer cells without harming normal tissues.

Investigators at Columbia University Medical Center (New York, NY, USA) created an adenovirus vector containing the genes for the transcription factors PEA-3 and AP-1. More...
These factors were known to trigger the conversion of inactive PROM-PEG cancer protein into active PEG-3 (progression-elevated gene-3), an apoptosis initiator. PROM-PEG is generally found in abundance in cancer cells but is not present in normal cells.

Results published in the January 25, 2005, issue of the Proceedings of the [U.S.] National Academy of Sciences revealed that tumors in mice receiving the vector died while normal tissues were not affected. The PEA-1/AP-1 combination was also found to act on melanoma, ovarian, breast, and glioma (brain) tumors.

"What is exciting is we may now be able to design a therapy that will seek out and destroy only cancer cells,” said senior author, Dr. Paul B. Fisher, professor of clinical pathology at Columbia University Medical Center. "We hope it will be particularly powerful in eradicating metastases that we cannot see and that cannot be eliminated by surgery or radiation. Gene therapy, especially for cancer, is really starting to make a comeback.”






Related Links:
Columbia University Medical Center

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.